Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Leases (2019 - 2023)

Ascendis Pharma A (ASND) has disclosed Current Leases for 5 consecutive years, with $15.3 million as the latest value for Q4 2023.

  • Quarterly Current Leases rose 8.59% to $15.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Dec 2023, up 8.59% year-over-year, with the annual reading at $15.3 million for FY2023, 8.59% up from the prior year.
  • Current Leases hit $15.3 million in Q4 2023 for Ascendis Pharma A, up from $14.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $15.3 million in Q4 2023 to a low of $6.5 million in Q4 2019.
  • Historically, Current Leases has averaged $10.4 million across 5 years, with a median of $8.2 million in 2020.
  • Biggest five-year swings in Current Leases: dropped 2.15% in 2021 and later skyrocketed 75.83% in 2022.
  • Year by year, Current Leases stood at $6.5 million in 2019, then grew by 25.25% to $8.2 million in 2020, then decreased by 2.15% to $8.0 million in 2021, then surged by 75.83% to $14.1 million in 2022, then rose by 8.59% to $15.3 million in 2023.
  • Business Quant data shows Current Leases for ASND at $15.3 million in Q4 2023, $14.1 million in Q4 2022, and $8.0 million in Q4 2021.